EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Immune-Mediated Membranoproliferative Glomerulonephritis during Pembrolizumab plus Bevacizumab Therapy in High-Grade Serous Ovarian Cancer: A Case Report

Michel Contreras, Rossana Reina, Jaime González-Montero, Tomás San Martín, Marcela Schultz, Carlos I Rojas, Mauricio Burotto iD

Case Reports in Oncology · 07.08.2026 · 19 (1) · 1566-1576

DOI: 10.1159/cro/abzag002 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 07.08.2026. Verfasst von Michel Contreras und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bradford Hill Clinical Research Center, Santiago, Chile. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICIs) have transformed oncologic care but are frequently associated with immune-related adverse events (irAEs). When used in combination with anti-angiogenic agents, such as bevacizumab, the risk of renal toxicity may be amplified and requires close monitoring. Case Presentation: We report the case of a 72-year-old woman with FIGO stage IIIC high-grade serous ovarian carcinoma treated with carboplatin, paclitaxel, bevacizumab, and pembrolizumab. After several cycles, the patient developed grade 2 hypertension, peripheral edema, nephrotic-range proteinuria, and hypoalbuminemia. Renal ultrasound was normal. Laboratory investigations revealed persistent eosinophilia, thrombocytopenia, and nephrotic syndrome. A kidney biopsy indicated immune complex-mediated membranoproliferative glomerulonephritis (MPGN) with severe podocytopathy. Comprehensive immunologic workup excluded differential diagnosis, supporting an ICI-related glomerular disease, potentially exacerbated by bevacizumab. Immunotherapy and anti-vascular endothelial growth factor therapy were discontinued. Renal function stabilized with conservative management, and corticosteroids were not required. Despite an improvement in proteinuria, the disease progressed and the patient was transitioned to a regimen of carboplatin plus pegylated liposomal doxorubicin.

Conclusion

This case highlights the diagnostic complexity and therapeutic dilemma posed by rare renal irAEs, such as MPGN, during combination immunotherapy. Prompt recognition, kidney biopsy, and multidisciplinary management are essential. As the use of combined regimens becomes more common, awareness of glomerular complications is critical to ensure preservation of renal function and guide oncologic decisions.

Schlagwörter

Stichwörter der Autor:innen

Case reportsImmune checkpoint inhibitorsMembranoproliferative glomerulonephritisNephrotic syndrome

Autor:innen und Institutionen

  • Bradford Hill Clinical Research Center, Santiago, Chile.
  • Finis Terrae University, Santiago, Chile.
  • Department of Medical Oncology, Clínica Santa María, Santiago, Chile.
  • Department of Pathology, Clínica Alemana, Santiago, Chile.

ORCID-Profile: Mauricio Burotto

Zitieren

APA

Contreras, M., Reina, R., González-Montero, J., San Martín, T., Schultz, M., Rojas, C. I., & Burotto, M. (2026). Immune-Mediated Membranoproliferative Glomerulonephritis during Pembrolizumab plus Bevacizumab Therapy in High-Grade Serous Ovarian Cancer: A Case Report. Case Reports in Oncology, 19(1), 1566-1576. https://doi.org/10.1159/cro/abzag002

Vancouver

Contreras M, Reina R, González-Montero J, San Martín T, Schultz M, Rojas CI, et al. Immune-Mediated Membranoproliferative Glomerulonephritis during Pembrolizumab plus Bevacizumab Therapy in High-Grade Serous Ovarian Cancer: A Case Report. Case Reports in Oncology. 2026;19(1):1566-1576. doi:10.1159/cro/abzag002

BibTeX
@article{Contreras2026,
  author = {Contreras, Michel and Reina, Rossana and González-Montero, Jaime and San Martín, Tomás and Schultz, Marcela and Rojas, Carlos I and Burotto, Mauricio},
  title = {Immune-Mediated Membranoproliferative Glomerulonephritis during Pembrolizumab plus Bevacizumab Therapy in High-Grade Serous Ovarian Cancer: A Case Report},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {1566--1576},
  doi = {10.1159/cro/abzag002}
}
Kostenlos starten →